- Conditions
- Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica, Dominant
- Interventions
- QR-313, Placebo
- Drug
- Lead sponsor
- Phoenicis Therapeutics
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Aurora, Colorado • Minneapolis, Minnesota + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dystrophic Epidermolysis Bullosa
- Interventions
- PTW-002 10 mg/g gel, Placebo
- Drug
- Lead sponsor
- Phoenicis Therapeutics
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Stanford, California • Worcester, Massachusetts • Cincinnati, Ohio
- Conditions
- Hidradenitis Suppurativa
- Interventions
- PTM-001, Placebo
- Drug
- Lead sponsor
- Phoenicis Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 3
- States / cities
- Redwood City, California • Worcester, Massachusetts • Cincinnati, Ohio